Please Wait.....
Report
Global Cell and Gene Therapy Business and Investment Opportunities - Analysis and Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update
Market Report I 2023-02-22 I 1350 Pages I BioIntel360
Insights and data in the report have been segmented under the following six modules:
Module 1: Global Cell and Gene Therapy Funding and Investments Outlook
This module provides insights and data related to cell and gene therapy partnerships and investment (research and development, mergers and acquisitions, product development, commercialization, licensing, and manufacturing) and allows a peek into the futuristic trends of cell and gene therapy technology investment area.
Module 2: Global Cell and Gene Therapy Clinical Trial Data Assessment
This module evaluates the data available from clinical trials conducted in this sector, representing a bird's eye view of emerging market dynamics and risks in the cell and gene therapy sector.
Module 3: Global Cell and Gene Therapy Patent Data Analysis
This module presents an exhaustive study of cell and gene therapy patent analytics at various levels, including strategic research planning as well as analyzing their potential applications.
Module 4: Competitive Landscape
This module provides detailed information along with a scoring matrix of key companies related to the cell and gene therapy industry, including their historical performance and the latest developments.
Module 5: Global Cell and Gene Therapy Market Size and Forecast
This module provides projections on the market's development during the years 2018-2027 after the profound evaluation of market dynamics at the deeper segmentation level. This report also provides an in-depth, data-centric analysis of the global cell and gene therapy market at regional and country levels:
Cell & Gene Therapy Market Size by Different Therapy Segment, 2018-2027
- Cell and Gene Modified Cell Therapies
- Gene Therapy and Genome Therapy
- DNA & RNA Therapeutics
Cell & Gene Therapy Market Size by Purpose of Manufacturing
- Commercial
- Clinical
Cell & Gene Therapy Market Size by Product
- Abecma
- Amondys
- Breyanzi
- Carvykti
- Givlaari
- Kimmtrak
- Kymriah
- Leqvio
- Luxturna
- Onpattro
- Oxlumo
- Rethymic
- Skysona
- Stratagraft
- Tecartus
- Tegsedi
- Viltepso
- Vyondys
- Yescarta
- Zolgensma
- Zynteglo
Cell & Gene Therapy Market Size by Route of Administration
- Injectables
- Infusions
- Bioscaffolds
- Topicals
Cell & Gene Therapy Market Size by Type of Cell
- CAR-T Cell
- TCR Cell
Cell & Gene Therapy Market Size by Type of Therapy
- T-Cell Therapies
- NK Cell
- Dendritic Cell Therapies
- Stem Cell Therapies
Cell & Gene Therapy Market Size by Source of Cell
- Autologous
- Allogenic
Cell & Gene Therapy Market Size by Delivery Mode
- In vivo
- ex-vivo
Cell & Gene Therapy Market Size by Source of Manufacturing
- In-House
- Contract Manufacturing
Cell & Gene Therapy Market Size by Therapeutic Class
- Oncology
- Neurology
- Ophthalmology
- Musculoskeletal
- Others
Cell & Gene Therapy Market Size by Technology
- Viral Vector Technology
- Cell Immortalization Technology
- Genome Editing Technology
- Others
Cell & Gene Therapy Market Size by End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Hospital & Clinics
Cell & Gene Therapy Market Size by Regions
- North America
- U. S.
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Germany
- Italy
- Netherlands
- Asia-Pacific
- China
- Japan
- Australia
- India
- South Korea
- MEA region
- Israel
- South Africa
- U.A. E
- Saudi Arabia
- Latin America
- Brazil
- Argentina
- Colombia
Key Companies Covered
- Gilead Company
- Novartis
- Roche Holding AG
- Johnson & Johnson
- Bristol Myers Squibb
- bluebird bio
- Alnylam Pharmaceuticals
Module 6 Regulatory Outlook
This module contains a detailed understanding of the ethical, legal, and social implications of cell and gene therapy technology.
This market intelligence report features an in-depth analysis on the current market dynamics of cell and gene therapy market.
It provides a detailed analysis of cell and gene therapy market dynamics, covering clinical trials, patent data, financial deals, and competitive landscape through 38 sections, 1048 tables, and 1513 charts.
Chapter 1 About this Report
1.1 Research Methodology
1.2 Definitions
1.3 Disclaimer
Chapter 2 Global Cell and Gene Therapy Market Outlook and Future Growth Dynamics
2.1 Introduction
2.2 Market Opportunities and Growth Dynamics
2.3 Strategy and Innovations
2.4 Regulation and Challenges Related to Cell and Gene Therapy Around the Globe
Chapter 3 Regulatory Dynamics Assessment Across Different regions
3.1 North America Cell and Gene Therapy Regulations
3.2 Europe Cell and Gene Therapy Regulations
3.3 Asia Pacific Cell and Gene Therapy Regulations
3.4 Latin America Cell and Gene Therapy Regulations
3.5 Middle East & Africa region Cell and Gene Therapy Regulation
Chapter 4 Global Cell and Gene Therapy Discovery and Clinical Pipeline Market Attractiveness
4.1 Cell and Gene Therapy Based: Discovery and Clinical Pipeline, 2023
4.2 Cell and Gene Therapy Based: Discovery and Clinical Pipeline, 2024
4.3 Cell and Gene Therapy Based: Discovery and Clinical Pipeline, 2025-2027
4.4 Approved Cell and Gene Therapies, 2017-2022
4.5 Anticipated Regulatory Decisions, 2023
4.6 Predicted Cell and Gene Therapy Product Launches, 2018-2030
4.7 List of Top 10 Innovation Driving Worldwide CGT Sales in 2022
4.8 FDA Approved Cell and Gene Therapies
Chapter 5 Global Cell and Gene Therapy Financial Deals & Alliances Market Dynamics & Outlook
5.1 Cell and Gene Therapy Financial Deals & Alliances Market Prediction and Estimation
5.2 Cell and Gene Therapy Financial Deals Vs Mergers & Acquisition, 2022 vs 2025
5.3 Cell and Gene Therapy Financial Deals Analysis by Different Therapy Segment, 2022 vs 2025
5.4 Cell and Gene Therapy Financial Deals Analysis by Type of Cell, 2022 vs 2025
5.5 Cell and Gene Therapy Financial Deals Analysis by Therapeutic Class, 2021 vs 2022
5.6 Cell and Gene Therapy Financial Deals Analysis by Therapeutic Class Prediction, 2022 vs 2025
5.7 Cell and Gene Therapy Financial Deals Analysis by Phase-Wise Deals, 2022 vs 2025
5.8 Cell and Gene Therapy Financial Deals Analysis by Type of Diseases, 2022 vs 2025
5.9 Cell and Gene Therapy Financial Deals Analysis by Type of Industry, 2022 vs 2025
5.10 Cell and Gene Therapy Financial Deals Analysis by Region, 2022 vs 2025
5.11 Cell and Gene Therapy Financial Deals Total Upfront Cash and Equity, 2018-2022
5.12 Number of Cell and Gene Therapy in Clinical Stage, 2018-2022
5.13 Recent Deals and Partnership of Cell and Gene Therapy
5.14 Recent Cell and Gene Therapy Mergers and Acquisitions
5.15 Global Cell and Gene Therapy Deals Landscape, 2020-2022
5.16 Cell and Gene Therapy Financial Deals Analysis by Funding and Investment
Chapter 6 Global Cell and Gene Therapy Patent Analysis & Outlook
6.1 Cell and Gene Therapy Historical and Futuristic Trend of Patent, 2018-2027
6.2 Cell and Gene Therapy Patent Analysis by Type of Cell Therapy Players, 2022 vs 2025
6.3 Cell and Gene Therapy Patent Analysis by Type of Gene Therapy Player, 2022 vs 2025
6.4 Cell and Gene Therapy Patent Analysis by Cell Type, 2022 vs 2025
6.5 Cell and Gene Therapy Patent Analysis by Product
6.6 Cell Therapy Patent Analysis by Patent Type, 2018-2022
6.7 Gene Therapy Patent Analysis by Patent Type, 2018-2022
6.8 Cell Therapy Patent Analysis by Legal Status, 2018-2022
6.9 Gene Therapy Patent Analysis by Legal Status, 2018-2022
6.1 Cell Therapy Patent Analysis by Top Patent Owners
6.11 Gene Therapy Patent Analysis by Top Patent Owners
6.12 Cell Therapy Patent Analysis by Top Patent Applicants
6.13 Gene Therapy Patent Analysis by Top Patent Applicants
6.14 Cell and Gene Therapy: Cell Therapy Top Patent Applicants Benchmarking Analysis
6.15 Cell and Gene Therapy: Gene Therapy Key Patent Applicant Benchmarking Analysis
6.16 Cell Therapy Patent Analysis by Published Status
6.17 Gene Therapy Patent Analysis by Published Status
6.18 Cell Therapy Patent Analysis by Investors
6.19 Gene Therapy Patent Analysis by Investors
6.20 Cell Patent Analysis by CPC Classification Code
6.21 Gene Therapy Patent Analysis by CPC Classification Code
6.22 Cell Therapy Patent Documents by Jurisdiction
6.23 Gene Therapy Patent Documents by Jurisdiction
6.24 List of Recent Cell Therapy Patents
6.25 List of Recent Gene Therapy Patents
Chapter 7 Cell and Gene Therapy Clinical Trial Analysis & Outlook
7.1 Cell and Gene Therapy Clinical Trial Historical and Futuristic Trend
7.2 Cell and Gene Therapy Clinical Trial Region-wise Prediction & Estimation, 2018-2027
7.3 Cell Therapy Clinical Trial Analysis by Country-wise Analysis
7.4 Gene Therapy Clinical Trial Analysis by Country-wise
7.5 Cell and Gene Therapy Clinical Trial Analysis by Age Group
7.6 Cell and Gene Therapy Clinical Trial Analysis by Funding Agency
7.7 Cell and Gene Therapy Clinical Trial Analysis by Documents
7.8 Cell and Gene Therapy Clinical Trial Analysis by Therapeutic Class
7.9 Cell and Gene Therapy Clinical Trial Analysis by Phase-wise
7.10 Cell and Gene Therapy Clinical Trial Analysis by Status
7.11 Number of Cell and Gene Therapy Assets in Clinical Pipeline
7.12 Cell and Gene Therapy Clinical Trial Analysis by Type of Diseases
7.13 Cell and Gene Therapy Clinical Trial Analysis by Study Type
Chapter 8 Cell and Gene Therapy Competitive Landscape Analysis: Key Company Profiles and Strategic Initiatives
8.1 Cell and Gene Therapy Competitive Index Ranking & Attractiveness Quadrant
8.2 Cell and Gene Therapy Company Market Share
8.3 Cell and Gene Therapy Competitive Mapping Quadrant
8.4 Cell and Gene Therapy Competitive Landscape by End Markets
8.5 Key Companies by Regions
8.6 Competitive Landscape by Different Therapy Segment of Cell and Gene Therapy
8.7 Gene Therapy Public Company Competitive Landscape
8.8 Cell Therapy Public Company Competitive Landscape
8.9 Cell and Gene Therapy Developers Worldwide
8.10 Gilead Sciences
8.11 Novartis
8.12 Johnson & Johnson
8.13 Bristol Myers Squibb
8.14 Roche Holding AG
8.15 bluebird bio
8.16 Alnylam Pharmaceuticals
Chapter 9 Global Cell and Gene Therapy Market Size and Forecast, 2018-2027
9.1 Cell and Gene Therapy Market Share by Different Therapy Segment, 2018-2027
9.1.1 Market Size by Cell and Gene Modified Cell Therapies, 2018-2027
9.1.2 Market Size by Gene Therapy and Genome Therapy, 2018-2027
9.1.3 Cell and Gene Therapy Market Size by DNA & RNA Therapeutics, 2018-2027
9.2 Cell and Gene Therapy Market Share by Purpose of Manufacturing, 2018-2027
9.2.1 Cell and Gene Therapy Market Size by Commercial, 2018-2027
9.2.2 Cell and Gene Therapy Market Size by Clinical, 2018-2027
9.3 Cell and Gene Therapy Market Share by Product, 2018-2027
9.4 Cell and Gene Therapy Market Share by Route of Administration, 2018-2027
9.4.1 Cell and Gene Therapy Market Size by Injectables, 2018-2027
9.4.2 Cell and Gene Therapy Market Size by Topicals, 2018-2027
9.4.3 Cell and Gene Therapy Market Size by Infusions, 2018-2027
9.4.4 Cell and Gene Therapy Market Size by Bioscaffolds, 2018-2027
9.5 Cell and Gene Therapy Market Share by Type of Diseases, 2018-2027
9.5.1 Cell and Gene Therapy Market Size by Rare Diseases, 2018-2027
9.5.2 Cell and Gene Therapy Market Size by Non-Rare Diseases, 2018-2027
9.6 Cell and Gene Therapy Market Share by Type of Cell, 2018-2027
9.6.1 Cell and Gene Therapy Market Size by CAR-T Cell, 2018-2027
9.6.2 Cell and Gene Therapy Market Size by TCR Cell, 2018-2027
9.7 Cell and Gene Therapy Market Share by Therapy, 2018-2027
9.7.1 Cell and Gene Therapy Market Size by T-Cell Therapies, 2018-2027
9.7.2 Cell and Gene Therapy Market Size by NK Cell, 2018-2027
9.7.3 Cell and Gene Therapy Market Size by Dendritic Cell Therapies, 2018-2027
9.7.4 Cell and Gene Therapy Market Size by Stem Cell Therapies, 2018-2027
9.8 Cell and Gene Therapy Market Share by Source of Cell, 2018-2027
9.8.1 Cell and Gene Therapy Market Size by Autologous, 2018-2027
9.8.2 Cell and Gene Therapy Market Size by Allogenic, 2018-2027
9.9 Cell and Gene Therapy Market Share by Delivery Mode, 2018-2027
9.9.1 Cell and Gene Therapy Market Size by In-vivo, 2018-2027
9.9.2 Cell and Gene Therapy Market Size by Ex-vivo, 2018-2027
9.10 Cell and Gene Therapy Market Share by Source of Manufacturing, 2018-2027
9.10.1 Cell and Gene Therapy Market Size by In-House, 2018-2027
9.10.2 Cell and Gene Therapy Market Size by Contract Manufacturing, 2018-2027
9.11 Cell and Gene Therapy Market Share by Therapeutic Class, 2018-2027
9.11.1 Cell and Gene Therapy Market Size by Oncology, 2018-2027
9.11.2 Cell and Gene Therapy Market Size by Neurology, 2018-2027
9.11.3 Cell and Gene Therapy Market Size by Ophthalmology, 2018-2027
9.11.4 Cell and Gene Therapy Market Size by Musculoskeletal, 2018-2027
9.11.5 Cell and Gene Therapy Market Size by Others, 2018-2027
9.12 Cell and Gene Therapy Market Share by Technology, 2018-2027
9.12.1 Cell and Gene Therapy Market Size by Viral Vector Technology, 2018-2027
9.12.2 Cell and Gene Therapy Market Size by Cell Immortalization Technology, 2018-2027
9.12.3 Cell and Gene Therapy Market Size by Genome Editing Technology, 2018-2027
9.12.4 Cell and Gene Therapy Market Size by Others Technologies, 2018-2027
9.13 Cell and Gene Therapy Market Share by End User, 2018-2027
9.13.1 Cell and Gene Therapy Market Size by Pharmaceutical & Biotechnology Companies, 2018-2027
9.13.2 Cell and Gene Therapy Market Size by Academic & Research Institutes, 2018-2027
9.13.3 Cell and Gene Therapy Market Size by Hospital & Clinics, 2018-2027
Chapter 9 - Chapter 38: This section contains chapters providing cell and gene therapy market sizing and forecast for additional 20 countries and 6 regions.
This report includes 1048 tables across various sections covering global, regional, and country level analysis. Due to space constraints, limited number of tables have been displayed here.
Table 1: Cell and Gene Therapy Financial Deals Market Size and Forecast, by Value (USD Million), 2018-2027
Table 2: Cell and Gene Therapy Financial Deals Market Size and Forecast, by Volume, 2018-2027
Table 3: Cell and Gene Therapy Fundings and Investment Market Size and Forecast, by Value (USD Million), 2018-2027
Table 4: Cell and Gene Therapy Fundings and Investment Market Size and Forecast, by Volume, 2018-2027
Table 5: Global Cell and Gene Therapy Market Size by Value (USD MM) 2018-2027
Table 5: Global Cell and Gene Therapy Market Size by Cell and Gene Modified Cell Therapies, by Value (USD MM), 2018-2027
Table 6: Global Cell and Gene Therapy Market Size by Gene Therapy and Genome Therapy, by Value (USD MM) 2018-2027
Table 7: Global Cell and Gene Therapy Market Size by DNA & RNA Therapeutics, by Value (USD MM) 2018-2027
Table 8: Global Cell and Gene Therapy Market Size by Commercial, by Value (USD MM) 2018-2027
Table 9: Global Cell and Gene Therapy Market Size by Clinical, by Value (USD MM) 2018-2027
Table 10: Global Cell and Gene Therapy Market Size by Injectables, by Value (USD MM) 2018-2027
Table 11: Global Cell and Gene Therapy Market Size by Topicals, by Value (USD MM) 2018-2027
Table 12: Global Cell and Gene Therapy Market Size by Infusions, by Value (USD MM) 2018-2027
Table 13: Global Cell and Gene Therapy Market Size by Bio scaffolds, by Value (USD MM) 2018-2027
Table 14: Global Cell and Gene Therapy Market Size by Rare Diseases, by Value (UDS MM) 2018-2027
Table 15: Global Cell and Gene Therapy Market Size by Non-Rare Diseases, by Value (UDS MM) 2018-2027
Table 16: Global Cell and Gene Therapy Market Size by CAR-T Cell, by Value (UDS MM) 2018-2027
Table 17: Global Cell and Gene Therapy Market Size by TCR Cell, by Value (UDS MM) 2018-2027
Table 18: Global Cell and Gene Therapy Market Size by T-Cell Therapies, by Value (USD MM), 2018-2027
Table 19: Global Cell and Gene Therapy Market Size by NK Cell, by Value (USD MM), 2018-2027
Table 20: Global Cell and Gene Therapy Market Size by Dendritic Cell Therapies, by Value (USD MM), 2018-2027
Table 21: Global Cell and Gene Therapy Market Size by Stem Cell Therapies, by Value (USD MM), 2018-2027
Table 22: Global Cell and Gene Therapy Market Size by Autologous (USD MM), 2018-2027
Table 23: Global Cell and Gene Therapy Market Size by Allogenic (USD MM), 2018-2027
Table 24: Global Cell and Gene Therapy Market Size by In-vivo, by Value (USD MM), 2018-2027
Table 25: Global Cell and Gene Therapy Market Size by Ex-vivo, by Value (USD MM), 2018-2027
Table 26: Global Cell and Gene Therapy Market Size by In-House, by Value (USD MM), 2018-2027
Table 27: Global Cell and Gene Therapy Market Size by Contract Manufacturing, by Value (USD MM), 2018-2027
Table 28: Global Cell and Gene Therapy Market Size by Oncology, by Value (USD MM), 2018-2027
Table 29: Global Cell and Gene Therapy Market Size by Neurology, by Value (USD MM), 2018-2027
Table 30: Global Cell and Gene Therapy Market Size by Ophthalmology, by Value (USD MM), 2018-2027
Table 31: Global Cell and Gene Therapy Market Size by Musculoskeletal, by Value (USD MM), 2018-2027
Table 32: Global Cell and Gene Therapy Market Size by Others, by Value (USD MM), 2018-2027
Table 33: Global Cell and Gene Therapy Market Size by Viral Vector Technology, by Value (USD MM), 2018-2027
Table 34: Global Cell and Gene Therapy Market Size by Cell Immortalization Technology, by Value (USD MM), 2018-2027
Table 35: Global Cell and Gene Therapy Market Size by Genome Editing Technology, by Value (USD MM), 2018-2027
Table 36: Global Cell and Gene Therapy Market Size by Others Technologies, by Value (USD MM), 2018-2027
Table 37: Global Cell and Gene Therapy Market Size by Pharmaceutical & Biotechnology Companies, by Value (USD MM), 2018-2027
Table 38: Global Cell and Gene Therapy Market Size by Academic & Research Institutes, by Value (USD MM), 2018-2027
Table 39: Global Cell and Gene Therapy Market Size by Hospital & Clinics, by Value (USD MM), 2018-2027
This report includes 1513 figures across various sections covering global, regional, and country-level analysis. Due to space constraints, the limited number of figures have been displayed here.
Figure 1: BioIntel360 Research Methodology
Figure 2: Cell and Gene Therapy Important Historical Events
Figure 3: Cell and Gene Therapy Readiness Scorecard for Selected Countries
Figure 4: Important Historical Events in Cell and Gene Therapy
Figure 5: List of Cell and Gene Therapy Projected Launch Year, 2023
Figure 6: List of Cell and Gene Therapy Projected Launch Year, 2024
Figure 7: List of Cell and Gene Therapy Projected Launch Year, 2025-2027
Figure 8: List of Approved Cell and Gene Therapies, 2017-2022
Figure 9: United States and European Union Anticipated Regulatory Decisions, 2023
Figure 10: List of Top 10 Innovations in Pipeline Expected to Drive Worldwide CGT Sales, 2022-2028
Figure 11: List of Top 10 Innovations Driving Worldwide CGT Sales in 2022
Figure 12: List of FDA Approved Cell and Gene Therapies 2017-2022
Figure 13: Cell and Gene Therapy Financial Deals & Alliances Market Size and Forecast, by Value (USD Million), 2018-2027
Figure 14: Cell and Gene Therapy Financial Deals & Alliances Market Share and Forecast, by Volume (%), 2018-2027
Figure 15: Global Cell and Gene Therapy: Financial Deals Vs Mergers & Acquisition Analysis, 2022 vs 2025
Figure 16: Global Cell and Gene Therapy Financial Deals: Analysis by Different Therapy Segment, 2022 vs 2025
Figure 17: Global Cell and Gene Therapy Financial Deals: Analysis by Type of Cell, 2022 vs 2025
Figure 18: Global Cell and Gene Therapy Financial Deals: Analysis by Therapeutic Class, 2021 vs 2022
Figure 19: Global Cell and Gene Therapy Financial Deals: Analysis by Therapeutic Class, 2022 vs 2025
Figure 20: Global Cell and Gene Therapy Financial Deals: Analysis by Phase-Wise Deals, 2022 vs 2025
Figure 21: Global Cell and Gene Therapy Financial Deals: Analysis by Type of Diseases, 2022 vs 2025
Figure 22: Global Cell and Gene Therapy Financial Deals: Analysis by Type of Industry, 2022 vs 2025
Figure 23: Global Cell and Gene Therapy Financial Deals: Analysis by Region, 2022 vs 2025
Figure 24: Cell and Gene Therapy Financial Deals Total Upfront Cash and Equity, 2018-2022
Figure 25: Cell and Gene Therapy Financial Deals Total Upfront Cash and Equity, 2018-2022
Figure 26: Recent Deals and Partnership of Cell and Gene Therapy
Figure 27: Recent Cell and Gene Therapy Mergers and Acquisitions
Figure 28: Global Cell and Gene Therapy Deals (> USD 1 Billion) Landscape, 2020-2022
Figure 29: Cell and Gene Therapy Fundings and Investment Market Size and Forecast, by Value (USD Million), 2018-2027
Figure 30: Cell and Gene Therapy Fundings and Investment Market Share and Forecast, by Volume (%), 2018-2027
Figure 31: Global Cell and Gene Therapy Fundings and Investment: Analysis by Region, 2018-2022
Figure 32: Global Cell and Gene Therapy Fundings and Investment: Analysis by Type of Industry, 2018-2022
Figure 33: Global Cell and Gene Therapy Fundings and Investment: Analysis by Therapeutic Class, 2018-2022
Figure 34: Global Cell and Gene Therapy Fundings and Investment: Analysis by Type, 2018-2022
Figure 35: Global Cell and Gene Therapy Fundings and Investment: Analysis by Funding Type, 2018-2022
Figure 36: Global Cell and Gene Therapy Fundings and Investment: Analysis by Funding Stage, 2018-2022
Figure 37: Cell and Gene Therapy Notable 2022 Start-up Companies
Figure 38: Cell and Gene Therapy Historic & Futuristics Trends of Patent, by Volume, 2018-2027
Figure 39: Cell and Gene Therapy Patent: Analysis by Type of Cell Therapy Players, 2022 vs 2025
Figure 40: Cell and Gene Therapy Patent: Analysis by Type of Gene Therapy Players, 2022 vs 2025
Figure 41: Cell and Gene Therapy Patent: Analysis by Cell Type, 2022 vs 2025
Figure 42: Cell and Gene Therapy Patent: Analysis by Product, 2022
Figure 43: Cell Therapy Patent: Analysis by Patent Type, 2018-2022
Figure 44: Gene Therapy Patent: Analysis by Patent Type, 2018-2022
Figure 45: Cell Therapy Patent: Analysis by Patent Legal Status, 2018-2022
Figure 46: Gene Therapy Patent: Analysis by Patent Legal Status, 2018-2022
Figure 47: Cell Therapy Patent: Analysis by Top Patent Owners, 2022
Figure 48: Gene Cell Therapy Patent: Analysis by Top Patent Owners, 2022
Figure 49: Cell Therapy Patent: Analysis by Top Patent Applicants, 2022
Figure 50: Gene Cell Therapy Patent: Analysis by Top Patent Applicants, 2022
Figure 51: Cell Therapy Key Patent Applicant: Texas University INC and Their CPC Classification Code Analysis, 2022
Figure 52: Cell Therapy Key Patent Applicant: University of California and Their CPC Classification Code Analysis, 2022
Figure 53: Cell Therapy Key Patent Applicant: Juno Therapeutics and Their CPC Classification Code Analysis, 2022
Figure 54: Cell Therapy Key Patent Applicant: University of Pennsylvania and Their CPC Classification Code Analysis, 2022
Figure 55: Cell Therapy Key Patent Applicant: Dana Farber Cancer Inst Inc and Their CPC Classification Code Analysis, 2022
Figure 56: Gene Therapy Key Patent Applicant: University of Texas and Their CPC Classification Code Analysis, 2022
Figure 57: Gene Therapy Key Patent Applicant: University of California and Their CPC Classification Code Analysis, 2022
Figure 58: Gene Therapy Key Patent Applicant: National Institute of Health and Medical Research and Their CPC Classification Code Analysis, 2022
Figure 59: Gene Therapy Key Patent Applicant: Research Institute Nationwide Children's Hospital and Their CPC Classification Code Analysis, 2022
Figure 60: Gene Therapy Key Patent Applicant: University of Pennsylvania and Their CPC Classification Code Analysis, 2022
Figure 61: Cell Therapy Patent: Analysis by Published Status, 2018-2022
Figure 62: Gene Therapy Patent: Analysis by Published Status, 2018-2022
Figure 63: Cell Therapy Patent: Analysis by Investors, 2022
Figure 64: Gene Therapy Patent: Analysis by Investors, 2022
Figure 65: Cell Therapy Patent: Analysis by CPC Classification Code, 2022
Figure 66: Gene Therapy Patent: Analysis by CPC Classification Code, 2022
Figure 67: Cell Therapy Patent: Analysis by Documents by Jurisdiction, 2022
Figure 68: Gene Therapy Patent: Analysis by Documents by Jurisdiction, 2022
Figure 69: List of Recent Cell Therapy Patents
Figure 70: List of Recent Cell Therapy Patents
Figure 71: Cell and Gene Therapy Clinical Trial Historical and Futuristics Trend, by Volume, 2018-2027
Figure 72: Cell and Gene Therapy Clinical Trial Region-wise Share and Forecast, by Volume (%), 2018-2027
Figure 73: Cell Therapy Clinical Trial: Analysis by Country-wise
Figure 74: Gene Therapy Clinical Trial: Analysis by Country-wise
Figure 75: Cell and Gene Therapy Clinical Trial: Analysis by Age Group
Figure 76: Cell and Gene Therapy Clinical Trial: Analysis by Funding Agency
Figure 77: Cell and Gene Therapy Clinical Trial: Analysis by Documents
Figure 78: Cell and Gene Therapy Clinical Trial: Analysis by Therapeutic Class, by Volume
Figure 79: Cell and Gene Therapy Clinical Trial: Analysis by Phase-wise
Figure 80: Cell and Gene Therapy Clinical Trial: Analysis by Status
Figure 81: Number of Cell and Gene Therapy Assets in Clinical Pipeline
Figure 82: Share of Cell and Gene Therapy in Pipeline Targeting Rare & Non-Rare Diseases
Figure 83: Cell and Gene Therapy Clinical Trial: Analysis by Study Type
Figure 84: Cell and Gene Therapy Companies Competitive Landscape
Figure 85: Cell and Gene Therapy: Companies by Market Share, 2022
Figure 86: Cell and Gene Therapy Companies Mapping Quadrant
Figure 87: Cell and Gene Therapy: Companies by End Users
Figure 88: Cell and Gene Therapy: Companies by Geography
Figure 89: Cell and Gene Therapy: Companies by Different Therapy Segment
Figure 90: Gene Therapy Public Company Competitive Landscape
Figure 91: Cell Therapy Public Company Competitive Landscape
Figure 92: Cell Therapy Public Company Competitive Landscape
Figure 93: Global Cell and Gene Therapy Market Size by Value (USD MM) 2018-2027
Figure 94: Global Cell and Gene Therapy Market Share by Different Therapy Segment (%), 2018-2027
Figure 95: Global Cell and Gene Therapy Market Size by Cell and Gene Modified Cell Therapies, by Value (USD MM), 2018-2027
Figure 96: Global Cell and Gene Therapy Market Size by Gene Therapy and Genome Therapy, by Value (USD MM) 2018-2027
Figure 97: Global Cell and Gene Therapy Market Size by DNA & RNA Therapeutics, by Value (USD MM) 2018-2027
Figure 98: Global Cell and Gene Therapy Market Share Purpose of Manufacturing (%), 2018-2027
Figure 99: Global Cell and Gene Therapy Market Size by Commercial, by Value (USD MM) 2018-2027
Figure 100: Global Cell and Gene Therapy Market Size, By Clinical, by Value (USD MM) 2018-2027
Figure 101: Global Cell and Gene Therapy Market Share by Product (%), 2018-2027
Figure 102: Global Cell and Gene Therapy Market Share by Route of Administration (%), 2018-2027
Figure 103: Global Cell and Gene Therapy Market Size by Injectables, by Value (USD MM) 2018-2027
Figure 104: Global Cell and Gene Therapy Market Size by Topicals, by Value (USD MM) 2018-2027
Figure 105: Global Cell and Gene Therapy Market Size by Infusions, by Value (USD MM) 2018-2027
Figure 106: Global Cell and Gene Therapy Market Size by Bio scaffolds, by Value (USD MM) 2018-2027
Figure 107: Global Cell and Gene Therapy Market Share by Type of Diseases (%), 2018-2027
Figure 108: Global Cell and Gene Therapy Market Share by Rare Diseases, by Value (UDS MM) 2018-2027
Figure 109: Global Cell and Gene Therapy Market Share by Non-Rare Diseases, by Value (UDS MM) 2018-2027
Figure 110: Global Cell and Gene Therapy Market Share by Type of Cell (%), 2018-2027
Figure 111: Global Cell and Gene Therapy Market Share by CAR-T Cell, by Value (UDS MM) 2018-2027
Figure 112: Global Cell and Gene Therapy Market Share by TCR Cell, by Value (UDS MM) 2018-2027
Figure 113: Global Cell and Gene Therapy Market Share by Therapy (%), 2018-2027
Figure 114: Global Cell and Gene Therapy Market Size by T-Cell Therapies, by Value (USD MM), 2018-2027
Figure 115: Global Cell and Gene Therapy Market Size by NK Cell, by Value (USD MM), 2018-2027
Figure 116: Global Cell and Gene Therapy Market Size by Dendritic Cell Therapies, by Value (USD MM), 2018-2027
Figure 117: Global Cell and Gene Therapy Market Size by Stem Cell Therapies, by Value (USD MM), 2018-2027
Figure 118: Global Cell and Gene Therapy Market Share by Source of Cell (%), 2018-2027
Figure 119: Global Cell and Gene Therapy Market Size by Autologous (USD MM), 2018-2027
Figure 120: Global Cell and Gene Therapy Market Size by Allogenic (USD MM), 2018-2027
Figure 121: Global Cell and Gene Therapy Market Share by Delivery Mode (%), 2018-2027
Figure 122: Global Cell and Gene Therapy Market Size by In-vivo, by Value (USD MM), 2018-2027
Figure 123: Global Cell and Gene Therapy Market Size by Ex-vivo, by Value (USD MM), 2018-2027
Figure 124: Global Cell and Gene Therapy Market Share by Source of Manufacturing (%), 2018-2027
Figure 125: Global Cell and Gene Therapy Market Size by In-House, by Value (USD MM), 2018-2027
Figure 126: Global Cell and Gene Therapy Market Size by Contract Manufacturing, by Value (USD MM), 2018-2027
Figure 127: Global Cell and Gene Therapy Market Share by Therapeutic Class (%), 2018-2027
Figure 128: Global Cell and Gene Therapy Market Size by Oncology, by Value (USD MM), 2018-2027
Figure 129: Global Cell and Gene Therapy Market Size by Neurology, by Value (USD MM), 2018-2027
Figure 130: Global Cell and Gene Therapy Market Size by Ophthalmology, by Value (USD MM), 2018-2027
Figure 131: Global Cell and Gene Therapy Market Size by Musculoskeletal, by Value (USD MM), 2018-2027
Figure 132: Global Cell and Gene Therapy Market Size by Others, by Value (USD MM), 2018-2027
Figure 133: Global Cell and Gene Therapy Market Share by Technology (%), 2018-2027
Figure 134: Global Cell and Gene Therapy Market Size by Viral Vector Technology, by Value (USD MM), 2018-2027
Figure 135: Global Cell and Gene Therapy Market Size by Cell Immortalization Technology, by Value (USD MM), 2018-2027
Figure 136: Global Cell and Gene Therapy Market Size by Genome Editing Technology, by Value (USD MM), 2018-2027
Figure 137: Global Cell and Gene Therapy Market Size by Others Technologies, by Value (USD MM), 2018-2027
Figure 138: Global Cell and Gene Therapy Market Share by End User (%), 2018-2027
Figure 139: Global Cell and Gene Therapy Market Size by Pharmaceutical & Biotechnology Companies, by Value (USD MM), 2018-2027
Figure 140: Global Cell and Gene Therapy Market Size by Academic & Research Institutes, by Value (USD MM), 2018-2027
Figure 141: Global Cell and Gene Therapy Market Size by Hospital & Clinics, by Value (USD MM), 2018-2027
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security